ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質(癌免疫療法用)

ACROBiosystems社 プロダクトリスト:Recombinant Protein

サプライヤー
AcroBioSystems
カタログNo.
CD0-H5268
製品名称
Human MS4A1 / CD20 Protein, Fc Tag
タンパク質名
MS4A1
Species
Human
HOST
HEK293
100ug: 87,000円
お問い合わせ
1mg: 567,000円
お問い合わせ

Overview

Synonyms MS4A1,CD20,MS4A-1
Characteristics This protein carries a human IgG1 Fc tag at the N-terminus. The protein has a calculated MW of 33.4 kDa. The protein migrates as 42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level Less than 1.0 EU per μg by the LAL method.
Purity >90% as determined by SDS-PAGE.
Description B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
Reference (1) Walport M, et al., 2008, Janeway's Immunobiology (7th ed.). New York: Garland Science.
(2) Bonilla FA, Bona CA., 1996, Textbook of Immunology. Boca Raton: CRC. p. 102.
(3) Cragg MS., 2005., Curr. Dir. Autoimmun. 8: 140?74.
URL http://www.acrobiosystems.com/P2390-Human-MS4A1--CD20-Protein-Fc-Tag.html

お問い合わせリスト(-)

お問い合わせフォーム